NYSE: CHE · Medical Care Facilities
Chemed (CHE) fair value: undervalued or overvalued?
As of 31 Oct 2026, Faircurve's model values Chemed (CHE) at $563.60 a share. The stock last closed at $533.77, which puts the model's fair value 5.6% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 5 Nov 2026. Chemed Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $529.32 to $563.60 (+6.5%). The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move.
What the model makes of itThe price of $533.77 is 5.6% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 24 Feb 2027. Options prices imply a move of about 9% either way over the next month. The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give CHE?
The calibrated range for CHE over 63 trading days is $484.30 to $601.52. It sits around the last close, and its width comes from the volatility that CHE's own options imply (33% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $451.56 to $699.22. In 57% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Chemed Corporation (CHE) provides hospice and palliative care through physicians, nurses, home health aides, social workers, clergy and volunteers, primarily in the United States.
Faircurve's model put the fair value at $563.60 a share on 31 Oct 2026, the midpoint of 2,000 simulations. The previous run, on 24 Oct 2026, gave $529.32, so the fair value moved +6.5%. The model's reason: the stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The calibrated range over 63 trading days is $500.12 to $614.74. Ranges built this way held the price 60% of the time at this horizon, across 6,661 past valuations. The evidence grade is Medium. It looks at input completeness, comparable companies and the spread of outcomes, but it does not say whether the fair value is right.
The model scores the business 82 out of 100 on quality against comparable companies. Profitability scores 100, with ROIC at 22.7% against a peer median of 9.5%. The balance sheet scores 87, with net debt to EBITDA at 0.77x against a peer median of 3.62x. The comparable companies are Hims & Hers Health, Inc., Universal Health Services, Inc., Concentra Group Holdings Parent, Inc., Option Care Health, Inc., The Ensign Group, Inc., DaVita Inc. and Encompass Health Corporation.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CHE report earnings, and how has the stock reacted?
Chemed's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.
Options prices on 5 Nov 2026 imply a move of about 6.0% in either direction through the nearest expiry, about 14 days out. That is the size the market is pricing, not a direction. CHE's 30 day implied volatility works out to about 9.4% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CHE's last 8 reports, ignoring direction, was 8.6%.
What the options market has priced for a month's move in CHE
How does CHE score on business quality?
Chemed's overall quality score is 82 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 22.7%ROIC | 9.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 87 | 1.05xFCF / net income | 0.97x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 56 | 4.1%Revenue growth, trailing | 21.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 74 | 7.5%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 87 | 0.77xNet debt / EBITDA | 3.62x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 75 | 0.7 ptsEBITDA margin downside volatility, 5y | 1.0 pts |
How does CHE compare with similar companies?
The companies in medical care facilities closest to Chemed in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| HIMS Hims & Hers Health, Inc. | $24.06 | $28.40 | +18.0% | Undervalued |
| UHS Universal Health Services, Inc. | $198.59 | $284.60 | +43.3% | Undervalued |
| CON Concentra Group Holdings Parent, Inc. | $42.15 | $42.06 | -0.2% | Fairly valued |
| OPCH Option Care Health, Inc. | $31.50 | $33.38 | +6.0% | Fairly valued |
| ENSG The Ensign Group, Inc. | $182.39 | $170.48 | -6.5% | Fairly valued |
| DVA DaVita Inc. | $194.82 | $207.11 | +6.3% | Fairly valued |
| EHC Encompass Health Corporation | $141.27 | $159.65 | +13.0% | Fairly valued |
| NHC National HealthCare Corporation | $207.62 | $255.41 | +23.0% | Low evidence grade |
What the comparable companies' multiples alone would give for CHE, the peer-implied price, is $721.35 a share on this run. The fair value weighs that against the company's own multiple.
All medical care facilities stocks ranked by gap to fair value
Chemed at a glance
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States.
- Market value
- $7.0B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Revenue expected, next twelve months
- $2.9B
- Consensus revenue growth, next fiscal year
- +8.0%
- Analysts with estimates
- 3
- Beta to the US market
- 0.00
- First valued by Faircurve
- 11 Jul 2026
At the close of 5 Nov 2026, 56.0% of the 1,065 graded US stocks the model covers traded below the model's fair value. CHE was among them.
How the fair value is worked out: the model prices Chemed on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for CHE was $529.32. As of 31 Oct 2026 it is $563.60, a change of +6.5%. The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Chemed's valuation
Is Chemed stock undervalued or overvalued?
On Faircurve's model, CHE reads as Fairly valued as of 31 Oct 2026. The model's fair value is $563.60 a share against a last close of $533.77, a gap of +5.6%.
What is CHE's fair value?
$563.60 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $451.56 to $699.22.
What price range does the model give CHE?
$484.30 to $601.52 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Chemed report earnings next?
The next report is scheduled for 24 Feb 2027. Companies can move their dates.
How much has CHE moved on past earnings reports?
Across its last 8 reports the median two session move was 8.6%, ignoring direction. The largest was -15.3% around the report of 25 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for CHE is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CHE
The model holds no idea open on CHE today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CHE with their outcomes. A free account is enough.